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Cell signalingThe A391E mutation in the transmembrane domain of ﬁbroblast growth factor receptor 3 leads to aberrant
development of the cranium. It has been hypothesized that the mutant glutamic acid stabilizes the dimeric
receptor due to hydrogen bonding and enhances its ligand-independent activation. We previously tested this
hypothesis in lipid bilayers and showed that the mutation stabilizes the isolated transmembrane domain
dimer by −1.3° kcal/mol. Here we further test the hypothesis, by investigating the effect of the A391E
mutation on the activation of full-length ﬁbroblast growth factor receptor 3 in Human Embryonic Kidney
293T cells in the absence of ligand. We ﬁnd that the mutation enhances the ligand-independent activation
propensity of the receptor by−1.7° kcal/mol. This value is consistent with the observed strength of hydrogen
bonds in membranes, and supports the above hypothesis.l rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
The ﬁbroblast growth factor receptors (FGFR1, 2, 3, and 4) play a
critical role in the development of the skeletal system [1–3]. These
receptor tyrosine kinases (RTKs) have extracellular domains consist-
ing of glycosylated Ig-like domains, single transmembrane (TM)
domains, and characteristic split tyrosine kinase domains. They bind
ligands from the fgf family in the presence of heparin and mediate
signaling cascades that induce cell growth, differentiation, migration
and chemotaxis, angiogenesis, and survival [1,2,4].
Mutations in the FGF receptors have been linked to dysplasias of
the skeletal system and the cranium. Many of these pathogenic
mutations occur inﬁbroblast growth factor receptor 3 (FGFR3). Almost
all documented FGFR3 mutations are associated with dwarﬁsm
syndromes of different severities: achondroplasia (ACH, the most
common form of human dwarﬁsm), thanatophoric dysplasia (TD,
lethal), and hypochondroplasia (HCH, mild) [3]. It has been demon-
strated that FGFR3 dwarﬁsm mutants exhibit higher phosphorylation
than wild-type in the absence of ligand [5–8]. Furthermore, the
increase in phosphorylation depends on the particular mutation, and
higher activation correlates with more severe phenotypes [7]. Thus, a
link between a particular dwarﬁsm mutation and enhanced ligand-
independent phosphorylation of the corresponding mutant has been
established.
A unique pathogenic mutation in FGFR3 was identiﬁed in 1995,
A391E, leading to disturbances of the growth of the cranium, rather
than the long bones. It is the genetic cause for Crouzon syndromewithacanthosis nigricans [9], an autosomal dominant disorder character-
ized by premature ossiﬁcation of the skull in the coronal area and skin
hyperpigmentation and hyperkeratosis. The A391Emutation has been
also identiﬁed as a somatic mutation in bladder cancer [10].
Two questions arise: [1] does the A391E mutation enhance ligand-
independent activation, similar to the numerous FGFR3 mutations
associated with dwarﬁsm phenotypes, and [2] what is the magnitude
of this effect, i.e. what is the change in FGFR3 activation propensity
due to the mutation? Previous biophysical studies have shown that
the A391E mutation stabilizes the isolated FGFR3 TM domain
homodimer in lipid bilayers by −1.3 kcal/mol [11,12]. This mecha-
nism could lead to over-stabilization of the unliganded FGFR3 dimers
in the plasma membrane, thus increasing ligand-independent
activation. If the increase in phosphorylation is due to hydrogen
bond-mediated dimer stabilization, then the change in activation
propensity will be similar to the value −1.3 kcal/mol measured for
dimer stabilization in lipid bilayers.
Thus far, the effect of the mutation has been studied within the
context of chimeric receptors, and these studies have produced
contradicting results. One study demonstrated that the mutation
increases the activation of a chimeric Neu receptor containing the
FGFR3 TM domain [13]. In another study, however, the A391E
mutation did not affect the downstream signaling of a chimeric
PDGF/FGF receptor in the PC12 cell line [14]. To resolve this
controversy and to gain insight into the molecular mechanism behind
the pathology, here we determine the effect on the A391E mutation
on FGFR3 ligand-independent activation within the context of the
full-length receptor. We use a method that allows us to determine the
change in FGFR3 activation propensity due to the mutation, such that
this change can be compared to the dimer stability measurements in
lipid bilayers.
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2.1. Plasmids
The plasmid encoding human wild-type FGFR3 (FGFR3/wt) in the
pcDNA 3.1+ vector was a generous gift from Dr. D.J. Donoghue, UCSD.
The mutant FGFR3 plasmid (FGFR3/A391E) was produced using a
Rapid Change Mutagenesis Kit XL II (Stratagene).
2.2. Cell culture and transfection
Human Embryonic Kidney 293T (HEK 293T) cells were cultured at
37 °C with 5% CO2 for 24 h. The cells were transfected with plasmids
encoding FGFR3/wt and FGFR3/A391E using Fugene 6 (Roche),
following the manufacturer's protocol. Varying levels of receptor
expression were achieved by varying the amount of plasmid used in
transfection. In all cases, cells were starved prior to the experiments, a
treatment which induces receptor accumulation in the plasma
membrane.
2.3. Immunostaining
Cells were cultured for 24 h after transfection, and then starved for
24 h. After ﬁxing with 4% paraformaldehyde (PFA), the cells were
blocked using 3% bovine serum albumin (BSA) for 1 h. Surface
localization of FGFR3 in HEK 293T cells was detected with FGFR3 (H-
100) antibodies (sc-9007, Santa Cruz Biotechnology), recognizing the
extracellular N-terminal domain, followed by FITC-conjugated goat
anti rabbit IgG (Invitrogen, CA), without cell permeabilization. Images
were acquired under identical conditions using a Nikon confocal
microscope.
2.4. Western blots
HEK293T cellswere cultured for 24 h following transfection, starved
in serum-free medium for 24 h and then treated with lysis buffer
(25 mM Tris-HCl, 0.5% Triton X-100, 20 mM NaCl, 2 mM EDTA, 2 mM
NaVO4 and protease inhibitor, Roche Applied Science). The lysates were
collected following centrifugation at 15,000 g for 15 min at 4 °C and
loadedonto 3–8%NuPAGE®Novex®Tris–Acetatemini gels (Invitrogen,
CA). The proteinswere transferred onto a nitrocellulosemembrane, and
blocked using 5% milk in TBS. FGFR3 total protein and phosphorylation
levels were probed with antibodies against FGFR3 (H-100; sc-9007,
Santa Cruz Biotechnology) and phospho-FGFR (Tyr653/654; Cell
Signaling Technology), respectively, followed by anti-rabbit HRP
conjugated antibodies (W4011, Promega). The proteins were detected
using the Amersham ECL detection system (GE Healthcare).
2.5. Titration with fgf1
Cells were starved overnight in serum-free medium, before fgf1
(Millipore, MA) was added at concentrations ranging from 5 ng/ml to
5000 ng/ml. After incubating for 10 min with fgf1 the cells were lysed
and analyzed by Western blot.
2.6. Quantiﬁcation of Western blots
The Western blot ﬁlms were scanned and processed using
ImageQuant TL. At least three independent experiments were per-
formed in order to determine averages and standard deviations. For
quantiﬁcation, the amount of protein lysate loaded onto gels was
adjusted such that all the band intensities were within the so-called
linear range, with intensities proportional to the receptor concentra-
tions [13].2.7. Flow cytometry measurements
HEK 293T cells were transfected with plasmids encoding the
wild-type and mutant FGFR3. Twenty-four hours later, cells were
starved in serum-free DMEM for another twenty-four hours. The cells
were dislodged from the culture dishes using 5 mM EDTA
and washed with ice cold 3% FBS/PBS. FGFR3 expressed on the cell
surface was stained with FGFR3 (H-100) antibodies (sc-9007, Santa
Cruz Biotechnology). The cells were then incubated in a solution of
ﬂuorescein conjugated anti-rabbit IgG (401314, EMD, NJ). Measure-
ments were performed with a FACS Calibur ﬂow cytometer (Beckon
Dickinson). HEK 293T cells that were not transfected served as
control.
3. Results
3.1. Expression of wild-type and mutant receptors
To study the effect of the A391Emutation on FGFR3 expression, we
ﬁrst performed immunostaining experiments. In these experiments,
HEK 293T cells were transfected with plasmids encoding wild-type
and mutant FGFR3, starved for 24 h to induce accumulation of
receptors on the plasma membrane [15], and immunostained with
anti-FGFR3 (H-100, Santa Cruz) antibodies, followed by FITC-
conjugated goat anti rabbit IgG (Invitrogen, CA), without cell
permeabilization. The results, shown in Fig. 1A, demonstrate that
both wild-type and mutant FGFR3 can be detected on the cell surface.
While the surface expression varied from cell to cell, there were cells
that exhibited very similar staining intensities for the wild-type and
the mutant (an example shown in Fig. 1B). A close inspection of
Fig. 1A shows, however, that when the cells were transfected with the
wild-type plasmid, the number of cells which exhibited membrane
ﬂuorescencewas greater as compared to the cells transfectedwith the
mutant plasmid. This suggests that the plasma membrane expression
of the receptors is decreased due to the mutation.
To gain further insight into the effect of the mutation on plasma
membrane expression, we performed ﬂow cytometry experiments
after cell starvation as described in Materials and methods. We
used an antibody to the extracellular domain of FGFR3 and a
ﬂuorescein conjugated anti-rabbit IgG secondary antibody. Fig. 2
compares the results for the wild-type and mutant receptor,
when 4 μg DNA was used for transfection. We see that the
distribution of cells transfected with either the wild-type or the
mutant receptor is shifted to higher ﬂuorescence intensities, as
compared to non-transfected cells. In addition, there is a right-shift in
the number of cells expressing the wild-type receptor, suggesting
that these cells may accumulate a greater number of receptors at
the cell surface than cells bearing the A391E mutant receptor.
In three independent experiments, cells bearing wild-type FGFR3
exhibited increased ﬂuorescence over A391E-bearing cells (not
shown), suggesting that the average concentration of the wild-type
receptors at the plasma membrane is greater than that of the A391E
receptors.
Next we compared the expression levels of wild-type FGFR3 and
the A391E mutant in HEK 293T cells using Western blotting (see
Fig. 3). The middle panel in Fig. 3 shows the total receptor levels,
while the bottom panel shows an actin loading control. For both
wild-type and mutant FGFR3 we observe two bands corresponding
to the intermediate, 120 kDa Endo H-sensitive FGFR3 found in the
ER/cis-Golgi, and the fully glycosylated mature 130 kDa FGFR3,
located predominantly on the plasma membrane [14,16]. Lane 1
corresponds to wild-type FGFR3, while lane 2 corresponds to the
mutant receptor, when 1 μg DNA was used for transfection in both
cases. From the middle panel in Fig. 3, we see that the intensities of
the 120 kDa immature FGFR3 are roughly similar for the wild-type
and mutant receptor, suggesting that the synthesis of the 120 kDa
Fig. 1. Immunostaining of HEK 293T cells expressing wild-type and mutant FGFR3 at the plasma membrane. Cells were cultured for 24 h after transfection and serum starved. After
ﬁxing with 4% paraformaldehyde (PFA), the cells were blocked using bovine serum albumin (BSA) for 1 h. The cells were incubated with anti-FGFR3 antibodies, followed by FITC-
conjugated goat anti rabbit IgG antibodies without cell permeabilization to identify wild-type andmutant receptors localized at the cell surface. (A) 10× objective; (B) 60× objective.
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intensity of the mature 130 kDa FGFR3 band, however, is stronger
for the wild-type than the mutant receptor. Thus, the expression of
the mature FGFR3, located predominantly in the plasma membrane,
is lower for the A391E mutant, consistent with the ﬂow cytometry
results in Fig. 2.The immunostaining, ﬂow cytometry, and Western blot results
suggest that the expression of the mutant receptor in the plasma
membrane is lower than the expression of the wild-type. One possible
explanation for this apparent decrease is impaired trafﬁcking of the
mutant receptor to the cell surface. There are previous reports about
defective trafﬁcking of FGFR3 mutants linked to skeletal dysplasias
Fig. 2. Flow cytometry data for HEK 293T cells expressing wild-type and mutant FGFR3.
Non-transfected cells served as control. FGFR3 expressed on the cell surface was probed
using anti-N-FGFR3 antibodies, followed by ﬂuorescein conjugated anti-rabbit IgG
antibodies.
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similar defect.
3.2. Phosphorylation of wild-type and mutant receptors
Next we investigated whether the A391E mutation affects the
phosphorylation of mature FGFR3 in the absence of ligand. The
phosphorylation was detected by Western blot using anti-phospho-
FGFR antibodies (anti-Y653/654, Cell Signaling Technology) [16].
These antibodies are speciﬁc for two phosphorylated tyrosines in the
activation loop of FGFR3, Y647 and Y648. The phosphorylation of
these two tyrosines is required for the activation of the kinase domain
and the phosphorylation of other intracellular tyrosine residues [20].
The top panel in Fig. 3 shows FGFR3 phosphorylation, in the
absence of ligand, when 1 μg of DNA is used for transfection. We see
that the intensities of the 130 kDa anti-Y653/654 bands of the wild-
type and the mutant receptor are similar (top panel), suggesting that
the phosphorylation levels are similar, while the total expression isFig. 3. Expression and phosphorylation of wild-type FGFR3 and the A391E mutant in
HEK 293T cells. HEK 293T cells were transfected with 1 μg DNA encoding FGFR3/wt
(lane 1) and FGFR3/A391E (lane 2). Cells were lysed after 24-hour culture and 24-hour
starvation, and subjected to Western blotting. The blots were probed using anti-FGFR3
antibodies to assess total receptor levels (middle panel) and using anti-Y653/654
antibodies to assess receptor phosphorylation levels (top panel). Actin is shown in the
bottom panel. Lanes have been removed for clarity.lower for the mutant (middle panel). Thus, it appears that the
mutation increases receptor phosphorylation in the absence of ligand.
Due to the different levels of plasmamembrane expression of thewild-
type and mutant receptors, however, it is difﬁcult to compare directly
the phosphorylation levels for a single set of samples on a Western
blot. To be able to carry out such a comparison, we determined the
active fractions of the 130 kDa wild-type and mutant receptors as a
function of their concentrations, and we calculated their activation
propensities, as described below.
We have previously demonstrated that we can determine active
RTK fractions if we treat with their ligands and measure RTK phos-
phorylation over a verywide range of ligand concentrations, including
very high ligand concentrations [16]: At high ligand concentration all
receptors that are exposed to ligand and capable of binding ligand are
driven to their liganded dimeric state [16]. At these levels, phosphor-
ylation is saturated and is not further increased when more ligand is
added, providing a measure of the maximum possible phosphoryla-
tion. Active receptor fractions in the absence of ligand are then
determined as the ratio of measured phosphorylation at zero ligand
over the maximum possible phosphorylation [13,16].
We used the ligand fgf1, known to bind and activate FGFR3, in these
experiments. Fig. 4A shows representative fgf1 titration experiments
for wild-type andmutant FGFR3 at ﬁxed receptor expressions. The top
panels show the phosphorylation of the receptors (detectedwith anti-
Y653/654 antibodies), while the bottom panels show the total
receptor levels (anti-FGFR3 antibodies). As expected, mature FGFR3,
localized primarily on the cell surface, responds to ligand and exhibits
an increase in phosphorylation, while the lower molecular weight
form of FGFR3, localized to the ER, is not affected. We further see that
the phosphorylation increases as more ligand is added until a plateau
is reached at high ligand concentration, as anticipated [16]. Special
attention was paid to ensure that we saturate receptor phosphoryla-
tion and not simply saturate the blotting membrane capacity. As
discussed previously [13,16], the band intensities were always within
the so-called linear range, where the band intensities are proportional
to the receptor concentrations. Here wewere interested in themature
fully-glycosylated 130 kDa receptor, and we thus quantiﬁed only the
130 kDa band using Image Quant TL. To place the results for the wild-
type and themutant on the same scale, themaximumphosphorylation
was assigned a value of 1 at high fgf1 concentrations. Results are shown
in Fig. 4B, and they show a wide plateau region, corresponding to
saturating ligand concentrations.
Based on the experiments shown in Fig. 4, the active receptor
fraction at a ﬁxed receptor expression, at zero ligand, wasmeasured as
follows: We ﬁrst transfected HEK 293T cells with wild-type or A391E
FGFR3, split the cell population after 24 h growth and 24 h of
starvation, and then incubated half of the cells with 2500 ng/ml fgf1
for 10 min. The cells were lysed and receptor phosphorylation was
measured using Western blotting. The active fraction was calculated
as the ratio: ½P0=½Psat , where [P]0 is the anti-Y653/654 band intensity in
the absence of ligand and [P]sat is the anti-Y653/654 band intensity at
saturating ligand concentration (2500 ng/ml fgf1).
We measured active fractions at zero ligand, as discussed above,
over a wide range of receptor expression, achieved via transfection
with different amounts of DNA. To validate the calculations of active
fraction for all receptor expression levels, we performed fgf1 titration
experiments such as the one shown in Fig. 4 while varying receptor
expression. In each case the phosphorylation was saturated at high
ligand concentration. In particular, the phosphorylation in response to
2500 ng/ml fgf1was always within the plateau region, no matter how
much wild-type or mutant DNA was used for transfection.
The values of ½P0=½Psat , calculated for various receptor expression
levels, are shown with symbols for the wild-type (solid squares) and
the A391E mutant (open circles) in Fig. 5. The x axis in Fig. 5 is the
Fig. 5. Active fraction of mature FGFR3 in the absence of ligand, as a function of its
expression. Varying levels of receptor expression were achieved by varying the amount
of plasmid used for transfection from 0.75 μg to 6 μg of plasmid. Phosphorylated FGFR3
fractions were measured by comparing phosphorylation levels in the absence of ligand
and at saturating fgf1 concentration (2500 ng/ml fgf1). The A391E mutant ( ) shows a
higher phosphorylated fraction than the wild-type (■). The data were ﬁtted to a simple
activation model (see scheme (1) and reference [13]), yielding the activation
propensities for the wild-type and mutant receptors. The effect of A391E on the
activation propensity was calculated as −1.7 kcal/mol.
Fig. 4. Effect of fgf1 concentration on FGFR3 phosphorylation. (A) Representative
Western blots, probed using anti-FGFR3 antibodies to assess total receptor levels
(bottom) and using anti-Y653/654 antibodies to assess receptor phosphorylation (top).
Top: cells transfected with 1 μg of the FGFR3/wt plasmid. Bottom: cells transfected with
2 μg of the FGFR/A391E plasmid. Cells were serum starved for 24 h, then fgf1was added
for 10 min to the serum-free medium, at concentrations ranging from 5 ng/ml to
5000 ng/ml. The phosphorylation of the mature 130 kDa FGFR3 increased as the ligand
concentration increased, and a plateau was reached above the concentration of
1000 ng/ml. (B) Graphical analysis of ligand induced wild-type and A391E receptor
phosphorylation. Receptor phosphorylation was proportional to the anti-Y653/654
band intensity and was assigned a value of 1 at saturating fgf1 concentrations.
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comparing the expression of the 130 kDa receptors to FGFR3
expression in the stable HEK293-fWT line, estimated to have
8.4×105 copies of mature FGFR3 per cell [16], on Western blots. To
convert the band intensities to receptor concentrations per unit area
of the plasma membrane, we assumed that the surface area of a
HEK293T cell is 300 μm2 (see also [16]).
In Fig. 5 we see that the ligand independent activation of the
mature A391E mutant receptor is higher than the activation of the
mature wild-type receptor, over a wide range of receptor concentra-
tions. Thus, the A391E mutation increases the propensity of FGFR3 for
ligand-independent activation.
3.3. Quantitative assessment of the phosphorylation increase due to the
mutation
As discussed previously [13,16,21], the measured active fraction at
zero ligand can be ﬁtted to the theoretical prediction of a simple RTK
activation model:
M + M↔
K
D: ð1ÞScheme (1) assumes that all monomers are inactive and all dimers
are active, and describes an apparent equilibriumbetween the inactive
monomers (M) and the active dimers (D) in the absence of ligand. This
model has been shown to give an adequate ﬁt of RTK phosphorylation
data [13], despite its simplicity. Themodel does not take explicitly into
account all events/interactions that regulate RTK phosphorylation.
Rather, all these events contribute to an apparent activation constantK
deﬁned as:
K =
D½ 
M½ 2 : ð2Þ
The active dimer fraction 2[D] /2([D]+[M]) was calculated
according to this model as discussed previously [13] and then ﬁtted
to the experimentally determined active fractions in Fig. 5. The ﬁts for
the wild-type and the mutant are shown in Fig. 5 with the dashed and
solid lines, respectively. Each ﬁt yielded the optimal value of the
apparent constant K, such that the values of K for the wild-type and
mutant receptor can be compared: KWT=78 nm2/receptor for the
wild-type and KA391E=1512 nm2/receptor for themutant. From these
values we estimated the change in the activation propensities due to
the mutation according to [13]:
ΔΔG = −RT lnKA391E
KWT
ð3Þ
Using Eq. (3) we calculated that the mutation increases the
propensity for activation by ΔΔG=−1.7 kcal/mol. As discussed in
detail previously [13], this value does not depend on the exact x
coordinate in Fig. 5, which is based on some roughly estimated values,
such as the area of a HEK 293T cell.
4. Discussion
Mutations responsible for dwarﬁsm syndromes map primarily to
ﬁbroblast growth factor receptor 3 (FGFR3). These dwarﬁsm syn-
dromes occur in three different severities: (i) the most common form
of human dwarﬁsm (achondroplasia, ACH), (ii) hypochondroplasia
(HCH), which is milder than achondroplasia, and (iii) the very severe
thanatophoric (lethal) dysplasia (TD) [3]. Examples of FGFR3
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for ACH, (ii) V381E for HCH, and (iii) R240C, R248C, S249C, G370C,
S371C, and Y373C for TD [3,5,22]. Previous studies have suggested that
these mutations increase the ligand-independent activation of FGFR3
[5,6,23–26]. Furthermore, studies of cysteine mutants linked to
skeletal dysplasia have demonstrated the formation of disulﬁde-
bonded mutant FGFR3 dimers believed to signal in the absence of
ligand [7,26,27].
TheA391Emutation in FGFR3 isunique, because it has been linked to
craniosynostosis (usually associated with FGFR2 mutations), rather
than skeletal dysplasias [3,9,28]. Based onmodel systemﬁndings [11], it
has been hypothesized that the mutation leads to dimer over-
stabilization and enhanced ligand-independent FGFR3 activation,
similarly to mutations linked to skeletal dysplasias. To test this
hypothesis, we investigated the effect of the A391E mutation on the
activation of full-length FGFR3 inHEK293T cells in the absence of ligand.
One important ﬁnding in this work is that the plasma membrane
expression of themutant is lower than thewild-type expression in HEK
293Tcells, under identical transfection conditions (seeFigs. 2 and3). It is
possible that the difference in plasma membrane expression is speciﬁc
to the cell type used in this study, or it could be a general effect that
occurs in all cell types. Skeletal dysplasia mutations are known to
impede the trafﬁcking of other FGFR3 mutant receptors to the plasma
membrane, resulting in their intracellular accumulation [5,15,25,29].
Our experiments suggest that a similar trafﬁcking defectmay occur due
to the A391E mutation, at least in HEK 293T cells. Alternatively, it is
possible that the enhanced activation causes enhanced degradation of
the activated 130 kDa form of the mutant A391E receptor.
Despite the fact that the plasma membrane expression of the
mutant was lower than the wild-type, we were able to compare their
phosphorylation (see Fig. 5). Our results demonstrate an increase in
FGFR3 phosphorylation due to the A391E mutation in HEK 293T cells.
Thus, the effect of the mutation on phosphorylation is similar to the
phosphorylation increase observed for the FGFR3 mutants linked to
skeletal dysplasias. Results obtained in a recent study of FGFR3
heterodimerization [30] (see data points at zero ligand in Figs. 8A and
C [30]), also show an increase in phosphorylation due to the A391E
mutation in a related, yet distinctly different cell line, HEK 293.
Themajor ﬁnding of thiswork is that the A391Emutation increases
the activation propensity of full-length FGFR3 by−1.7 kcal/mol. This
value is consistent with the observed strength of hydrogen bonds in
membranes [31]. It is also similar to the stabilization of the isolated
A391E mutant TM domain dimer in lipid bilayers, −1.3 kcal/mol,
which is believed to occur due to hydrogen bonding of the side chain of
Glu391 with the backbone of the neighboring helix in the homodimer
[11,12]. Such an effect represents a change in the physical interactions
between the two receptors in the dimer, and is not expected to be cell
type-speciﬁc (although the composition of the membrane may
modulate its strength [32,33]). Thus, the increase in FGFR3 activation
due to the A391E mutation that we measure here is consistent with
hydrogen-bondmediated stabilization of FGFR3 unliganded dimers in
the plasma membrane.
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